Initial Dip in Estimated Glomerular Filtration Rate After Dapagliflozin Affects Renal Function in Chronic Phase in Chronic Heart Failure
Raisa Ogata, Takato Kotaki, Kozue Tanaka, Kyoko Higuchi, Natsumi Kumano, Kyoji Furukawa, Yoshihiro Fukumoto

TL;DR
This study shows that a temporary drop in kidney function after starting dapagliflozin in heart failure patients may predict long-term kidney outcomes.
Contribution
The study identifies risk factors for a temporary eGFR decline and its long-term renal impact in CHF patients on dapagliflozin.
Findings
Older age, hypertension, diabetes, and higher baseline eGFR are risk factors for the initial eGFR dip.
An initial dip is associated with a persistent decline in eGFR over 6 months to 1 year.
The initial dip may indicate long-term renoprotective effects of dapagliflozin.
Abstract
Background: Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been shown to improve prognosis in patients with chronic heart failure (CHF), in whom a transient decline in the estimated glomerular filtration rate (eGFR), known as the “initial dip,” is often observed within the first 1–2 weeks of SGLT2 inhibitor therapy. This study aimed to investigate the factors associated with this initial dip and its impact on long-term renal function in patients with CHF initiating dapagliflozin. Methods and Results: This retrospective study included 123 consecutive CHF patients who were started on dapagliflozin at our institution. The presence of an initial dip was defined as a decrease in the eGFR of ≥5 mL/min/1.73 m2 within two weeks of initiating therapy. Baseline clinical characteristics and renal function data were analyzed. Older age, hypertension, diabetes mellitus, and a…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes Treatment and Management · Chronic Kidney Disease and Diabetes · Pancreatic function and diabetes
